Rubella virus vaccine
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Rubella virus vaccine is a vaccine used to prevent Rubella.
- Brand Names
- M-M-R II, Proquad
- Generic Name
- Rubella virus vaccine
- DrugBank Accession Number
- DB10317
- Background
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Rubella virus (vaccine strain RA27/3) live antigen
- Rubella virus live antigen, A
- Rubella virus strain Wistar RA 27/3 live (attenuated) antigen
- Rubella virus strain Wistar RA 27/3 live antigen
- Rubella virus vaccine live (Wistar RA 27-3 strain)
- Rubella virus vaccine live attenuated (Wistar RA27/3 strain)
- Rubella virus vaccine,live
- Rubella, live attenuated
- Rubivirus rubella virus Wistar RA 27/3 whole
Pharmacology
- Indication
Rubella virus vaccine is used to prevent rubella in combination with other virus vaccines, such as the mumps and measles virus vaccine.1,2,3
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Abacavir. Abatacept The risk or severity of infection can be increased when Rubella virus vaccine is combined with Abatacept. Acyclovir The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Acyclovir. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Rubella virus vaccine. Adefovir dipivoxil The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Adefovir dipivoxil. Aldesleukin The risk or severity of infection can be increased when Rubella virus vaccine is combined with Aldesleukin. Alefacept The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alefacept. Alemtuzumab The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alemtuzumab. Altretamine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Altretamine. Amantadine The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Amantadine. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Meruvax II
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Rubella Virus Vacc Live Att Freez Dried Inj Powder, for solution 1000 unit / vial Subcutaneous Iaf Biovac Inc. 1991-12-31 1997-08-20 Canada Rubella Virus Vaccine Live Dried Attenuated Powder, for solution 1000 unit / 0.5 mL Subcutaneous Aventis Pasteur Limited 1983-12-31 2000-04-07 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image M-M-R II Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous A-S Medication Solutions 1971-04-21 Not applicable US M-M-R II Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Physicians Total Care, Inc. 1996-08-07 2012-06-30 US M-M-R II Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Merck Sharp & Dohme Llc 1971-04-21 Not applicable US M-M-R II Rubella virus vaccine (1000 TCID50/0.5mL) + Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL) Powder, for solution Subcutaneous Merck Ltd. 1979-12-31 Not applicable Canada M-M-R II VACCINE Rubella virus vaccine (1000 CCID50/0.5mL) + Measles virus vaccine live attenuated (1000 CCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 CCID50/0.5mL) Injection, powder, for solution Subcutaneous MSD PHARMA (SINGAPORE) PTE. LTD. 1988-06-24 Not applicable Singapore M-M-rvaxpro Rubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) Merck Sharp & Dohme B.V. 2021-02-10 Not applicable EU M-M-rvaxpro Rubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) Merck Sharp & Dohme B.V. 2021-02-10 Not applicable EU M-M-rvaxpro Rubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) Merck Sharp & Dohme B.V. 2021-02-10 Not applicable EU M-M-rvaxpro Rubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) Injection, powder, for suspension Intramuscular; Subcutaneous Merck Sharp & Dohme B.V. 2021-02-10 Not applicable EU M-M-rvaxpro Rubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50) Injection, powder, for suspension Intramuscular; Subcutaneous Merck Sharp & Dohme B.V. 2021-02-10 Not applicable EU
Categories
- ATC Codes
- J07BD53 — Measles, combinations with rubella, live attenuatedJ07BD54 — Measles, combinations with mumps, rubella and varicella, live attenuatedJ07BD52 — Measles, combinations with mumps and rubella, live attenuatedJ07BJ01 — Rubella, live attenuatedJ07BJ51 — Rubella, combinations with mumps, live attenuatedJ07BD51 — Measles, combinations with mumps, live attenuated
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 52202H034Z
- CAS number
- Not Available
References
- General References
- TITCK Product Information: R-VAC (rubella vaccine, live, attenuated) for subcutaneous injection [Link]
- DailyMed: Proquad (measles, mumps, rubella, and varicella live vaccine) lyophilized powder for injection [Link]
- FDA Approved Drug Products: PRIORIX (Measles, Mumps, and Rubella Vaccine, Live), suspension for subcutaneous injection [Link]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Children / Death / Measles Vaccination / Morbidity / Non-specific/Heterologous Effects of Vaccines / Oral Polio Vaccine 1 4 Completed Not Available Rheumatoid Arthritis, Juvenile 1 4 Completed Diagnostic Diphtheria / Measles / Pertussis / Tetanus 1 4 Completed Prevention Adverse Event Following Immunization / Measles / Mumps / Rubella 1 4 Completed Prevention BCG Infection / Immune Responses / Vaccine Reaction 1 4 Completed Prevention Chickenpox / Hepatitis A / Measles / Mumps / Rubella 1 4 Completed Prevention Death / Vaccines 1 4 Completed Prevention Hepatitis A Virus 1 4 Completed Prevention Hepatitis A / Measles / Mumps / Rubella 1 4 Completed Prevention Immunogenicity / Safety Issues 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Subcutaneous Injection, powder, lyophilized, for suspension Subcutaneous Powder, for solution Subcutaneous Injection, powder, for solution Subcutaneous 1000 CCID50/0.5mL Injection, powder, for suspension Intramuscular; Subcutaneous Liquid; powder, for solution Subcutaneous Injection, powder, for solution Intramuscular; Subcutaneous Injection, powder, for solution Subcutaneous Kit; powder, for solution Intramuscular; Subcutaneous Injection, solution Intramuscular; Subcutaneous Injection Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous Powder, for solution Intramuscular; Subcutaneous Injection, powder, lyophilized, for suspension Intramuscular; Subcutaneous Injection Subcutaneous 0.5 ml Powder, for solution Subcutaneous 1000 unit / vial Powder, for solution Subcutaneous 1000 unit / 0.5 mL Injection Subcutaneous Injection, powder, lyophilized, for suspension Subcutaneous Solution Injection, powder, lyophilized, for suspension Powder - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:03 / Updated at October 02, 2023 21:58